Ribo Life Science Passes HKEX Listing Hearing: Strong Technological Moat and Focused Pipeline Bring a Rare Innovative Drug Asset to Hong Kong Market

As Ribo Life Science, a key pioneer of China's small nucleic acid drugs, passes the Hong Kong Stock Exchange listing hearing, the Hong Kong stock market has gained another innovative drug stock of significant scarcity value.

On December 21, according to the disclosure on the HKEX official website, Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to as "Ribo Life Science") has passed the main board listing hearing of the Hong Kong Stock Exchange (HKEX). CICC and Citibank are the joint sponsors. The company is a major player in the global small nucleic acid drug research and development field, particularly focusing on siRNA therapies. Currently, Ribo Life Science has become one of the companies with the largest siRNA drug pipelines globally, with seven self-developed drug assets currently in clinical trial stages.

From the perspective of industry development trends, the small nucleic acid drug track where Ribo Life Science is positioned is currently regarded as the "third wave" following small molecule and antibody drugs. Compared with traditional small molecule and antibody drugs, it offers a broader range of candidate targets, shorter development cycles, better targeting, and higher specificity, and is in a period of rapid growth. According to Frost & Sullivan, the global small nucleic acid therapy market is expected to reach $18.6 billion by 2029, with a compound annual growth rate (CAGR) of 29.5% from 2024 to 2029.

But due to the high technical barriers in the small nucleic acid drug industry, especially in delivery technology, how to precisely, efficiently, and safely deliver drugs to target organs (such as intrahepatic and extrahepatic) is the core challenge of the industry. Therefore, innovative pharmaceutical companies in China, like Ribo Life Science, that can break through these technical barriers and are approaching commercialization are indeed rare.

Of course, the success of Ribo Life Science was not achieved overnight, but rather is the result of the combined effects of its pipeline layout, technical strength, and strategic determination.

From the pipeline layout, Ribo Life Science deeply focuses on the golden track of small nucleic acids, starting from rare diseases and expanding to common diseases, with a rich and balanced pipeline layout, indicating immense long-term development potential.

Intelligent Finance Observer noted that, unlike most traditional pharmaceutical companies that focus on chemical drugs and biologics, Ribo Life Science is highly specialized in the cutting-edge field of small nucleic acid drugs. Currently, the company has seven self-developed drugs in clinical trial stages, covering eight indications related to cardiovascular, metabolic, kidney, and liver diseases. Among them, four are in Phase 2 clinical trials, and its HDV-targeting product RBD1016 received orphan drug designation from the EMA in October 2025. In addition to its clinical pipeline, the company also has over 20 preclinical projects planned for advancement into clinical development.

Among them, the core product RBD4059 (an siRNA targeting FXI) is the world's first and fastest-progressing siRNA drug in clinical development for the treatment of thrombotic diseases. It completed patient enrollment for the Phase 2a clinical trial in February 2025 and is expected to complete the trial by the end of 2025.

In addition, the company's RBD5044 (an siRNA targeting APOC3) and RBD7022 (an siRNA targeting PCSK9) are two promising drug candidates with strong development potential. RBD5044 is primarily used for treating hypertriglyceridemia (HTG) and is the second siRNA globally to enter clinical development targeting APOC3. Currently, a Phase 2 trial for this drug in patients with mixed dyslipidemia is ongoing in Sweden. Meanwhile, RBD7022, used for treating hypercholesterolemia, is also the second siRNA globally to enter clinical development targeting PCSK9. The Phase 1 trial of RBD7022 was completed in China in March 2025, and its Phase 2 clinical trial is now being advanced by the partner Qilu Pharmaceutical.

It can be seen that Ribo Life Science’s pipeline includes both drugs for rare diseases like Hereditary Angioedema and drugs for common diseases with a large patient base such as hypercholesterolemia and hypertension. This layout not only allows the company to establish its brand and achieve commercialization in the short term through rare disease drugs, but also provides significant market potential for long-term development.

In terms of technical strength, Ribo Life Science has not only built a technological moat by overcoming the industry's "bottleneck" problem (delivery technology), but also created a long-term "innovation engine" for the company through its independent technology platform, with obvious competitive advantages.

It is reported that Ribo Life Science is one of the few companies in the world with independently developed and clinically validated GalNAc delivery technology. This technology, based on specific delivery of siRNA drugs, enhances efficacy and improves safety, revolutionizing the treatment concept of innovative drugs. Among its assets, the company’s liver-targeted RiboGalSTAR™ delivery technology serves as the cornerstone for many pipeline assets, addressing a key challenge in siRNA therapy — efficient and specific delivery. This has undoubtedly overcome one of the industry's most critical "bottleneck" issues, establishing a strong technical moat for the company.

With this platform, Ribo Life Science is able to achieve efficient and rapid drug development targeting various hepatic disease targets, ultimately forming a "platform-based" pipeline production capability. Meanwhile, significant progress has been made in Ribo Life Science’s other organ and tissue delivery technology platforms outside the liver, such as the RiboPepSTARTM delivery platform for kidneys, the central nervous system, adipocytes, muscle, and other metabolic tissues, as well as the RiboOncoSTAR™ delivery platform for tumors, placing the company at the forefront of global small nucleic acid development.

With the strong technical moat and forward-looking product pipeline layout mentioned above, Ribo Life Science's revenue is growing rapidly, and it is expected to achieve the leap from Biotech to Biopharma in the near future.

According to the prospectus, Ribo Life Science achieved a revenue of 143 million yuan in 2024, with an income of 66 million yuan in the first half of 2024, which further grew to 103 million yuan in the first half of 2025.

The steady increase in the company's recent revenue is mainly attributed to its strategic cooperation with leading international and Chinese pharmaceutical companies and the smooth progress of these partnerships. Since December 2023, Ribo Life Science has successively signed collaboration and licensing agreements with Qilu Pharmaceutical and Boehringer Ingelheim. In the first half of 2025, the first research and development milestones were achieved, successfully triggering milestone payments.

These collaborations not only bring阶段性收入 to the company but also serve as significant endorsements of its R&D capabilities and platform potential. Subsequently, as Ribo Life Science's key drugs are successively launched, leveraging its strong brand effect, the company will also gain sufficient momentum to transform from a research-oriented company into a comprehensive pharmaceutical enterprise with commercialization capabilities.

In addition, Ribo Life Science's steady and well-planned international strategic layout — including overseas R&D centers with self-developed Phase II clinical trial bases, a global clinical application strategy, and a high-level world-class R&D team — will not only further consolidate and enhance the company’s own global competitiveness but also lead China’s small nucleic acid industry to more deeply and systematically reshape the competitive landscape of the global biopharmaceutical industry.

Overall,The benchmark significance of Ribo Life Science lies not only in its identity as a pioneer of small nucleic acids in China, but also in its successful validation of a differentiated path focused on cutting-edge innovation.Faced with the challenges of high technical barriers and long R&D cycles, many pharmaceutical companies have hesitated due to either insufficient technical accumulation or the short-term nature of capital and strategy. In contrast, Ribo Life Science has established its leading position in this field by leveraging core technologies and a long-term perspective.

Hence, Ribo Life Science's IPO in Hong Kong this time clearly offers investors a rare opportunity to participate in China's small nucleic acid drug innovation wave.